Thursday, August 24, 2023 Omicron-Targeted SARS-CoV-2 Vaccine: Similar Antibody Response Whether 1 Boost or 2 Caption: Scanning electron micrograph of a cell (purple) infected with the Omicron strain of SARS-CoV-2 virus particles (orange), isolated from a patient sample. Credit: NIAID   A study evaluating the benefit of booster vaccines for SARS-CoV-2, the virus that causes COVID-19, has found no increased antibody response from having two booster doses compared to one; in both scenarios people had already received an approved primary series and booster vaccines. The phase 2 trial results, from the COVAIL study team (Coronavirus Variant Immunologic Landscape), are published in the Journal of Infectious Diseases. The study enrolled 202 participants from March through May 2022, 100 of whom received a single additional boost and the remainder two boosts, given two months apart. The trial used a Moderna bivalent vaccine that targeted the Omicron and Beta variants of the virus. The researchers noted, however, that "additional doses of variant boosters are recommended for individuals at risk for severe disease." They also stated that a new updated Omicron XBB.1.5 formulation for COVID-19 vaccine boost is being developed for fall 2023. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107